Author Archives: Patricia Inacio, PhD

SLE Pathogenesis and Imbalances in T-cell Signaling

A recent review summarized the current knowledge on how unbalanced T-cell signaling characterizes systemic lupus erythematosus (SLE) disease. The review study, titled “Disturbed T Cell Signaling and Altered Th17 and Regulatory T Cell Subsets in the Pathogenesis of Systemic Lupus Erythematosus,” was published in the journal Frontiers in…

Cognitive Impairment in SLE May Be Predicted by Vitamin D Deficiency

Deficiency of a specific form of vitamin D (25(OH)D3) is associated with and independently predicts worse cognitive function in systemic lupus erythematosus (SLE) patients, according to a study in the journal PLOS One. The report is titled “25-Hydroxyvitamin D3 Deficiency Independently Predicts Cognitive Impairment in Patients with Systemic Lupus Erythematosus.” SLE…

Risk of Systemic Lupus Erythematosus Linked To Genetic Variation

Researchers identified that a single nucleotide polymorphism in the sequence of the CD40 gene, a gene with key functions in immune diseases, is associated with susceptibility to systemic lupus erythematosus. The study entitled “The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus” was…

Diffuse Alveolar Haemorrhage Reduces SLE Patients’ Long-term Survival

In a recent study entitled “Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival” researchers performed the first study investigating the risk factors for diffuse alveolar haemorrhage in systemic lupus erythematosus and how it impacts patients’ therapy responses and outcomes. The study was published…

Blisibimod: Potential Treatment for Systemic Lupus Erythematosus

In a new study entitled “Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials” authors determined the safety, tolerability and efficacy of blisibimod, a B cell-activating factor antagonist, in patients with systemic…